The CHD challenge: Comparing four cost-effectiveness models

Value in Health

Volumn 14, Issue 1, 2011, Pages 53-60

  Turner, David ^a   Raftery, James ^a   Cooper, Keith ^a   Fairbank, Eleanor ^a   Palmer, Stephen ^b   Ward, Sue ^c   Ara, Roberta ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Coronary disease; Cost utility analysis; Economic modeling; Model validation

Indexed keywords

CLOPIDOGREL; STATIN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TICLOPIDINE;

ARTICLE; CONSENSUS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MODEL; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STRUCTURE ANALYSIS; UNITED KINGDOM; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; MALE; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; STATISTICS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY DISEASE; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; PLATELET AGGREGATION INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TICLOPIDINE;

EID: 79952689035     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.10.009     Document Type: Article

References (26)

1. Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8:1-158.
2. Burch J, Paulden M, Conti, et al. Antiviral drugs for the treatment of influenza: a Systematic Review and Economic Evaluation. Health Technol Assess 2009;13:1-265.
3. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479-500. (Pubitemid 30398806)
4. National Institute for Health and Clinical Excellence (NICE). NICE, guide to the methods of technology appraisal. Available from: URL: http://www.nice.org.uk [Accessed November 1, 2010].
5. Cooper K, Davies R, Roderick P, et al. The development of a simulation model of the treatment of coronary heart disease. Health Care Management Science 2002;5:259-67. (Pubitemid 41450971)
6. Cooper K, Davies R, Raftery J, Roderick P. Use of a coronary heart disease simulation model to evaluate the costs and effectiveness of drugs for the prevention of heart disease. J Oper Res Soc 2008;59:1173-81.
7. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-160.
8. Vergel YB, Palmer S, Asseburg C, et al. Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis. Heart 2007;93:1238-43. (Pubitemid 47492912)
9. Main C, Palmer S, Griffin S, et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess 2004;8:1-141.
10. Palmer S, Sculpher M, Philips Z, et al. Management of non-ST-elevation acute coronary syndromes: How cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service. Int J Cardiol 2005;100:229-40.
11. Mauskopf JA, Boye KS, Schmitt C, et al. Adherence to guidelines for sensitivity analysis: cost-effectiveness analysis of dual oral antiplatetlet therapy. J Med Econ 2009;12:141-53.
12. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. (Pubitemid 32758501)
13. Wailoo A, Goodacre S, Sampson F, et al. Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty project. Heart 2010;96:668-72.
14. Karnon J, Brennan A, Akehurst R. A critique and impact analysis of decision modelling assumptions. Med Decis Making 2007;27:491-9. (Pubitemid 47106936)
15. British Cardiac Society Guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and Evaluation Unit. Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. Heart 2001;85:133-42.
16. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23:1809-40.
17. Capewell S, Murphy NF, MacIntyre K, et al. Short-term and long-term outcomes in 133, 429 emergency patients admitted with angina or myocardial infarction in Scotland, 1990-2000: population-based cohort study. Heart 2006;92:1563-70. (Pubitemid 44629156)
18. Murphy NF, Stewart S, Hart CL, et al. A population study of the long-term consequences of Rose angina: 20-year followup of the Renfrew-Paisley study. Heart 2006;92:1739-46. (Pubitemid 44851314)
19. Hobbs FD, Roalfe AK, Davis RC, et al. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J 2007;28:1128-34. (Pubitemid 47343888)
20. Gray D, Hampton JR. Twenty years' experience of myocardial infarction: the value of a heart attack register. Br J Clin Pract 1993;47:292-5. (Pubitemid 23355322)
21. Brown JB, Palmer AJ, Bisgaard P, et al. The Mt. Hood challenge: cross-testing two diabetes simulation models. Diabetes Res Clin Pract 2000;50(Suppl. 3):S57-S64.
22. The Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638-46.
23. Pignone M, Russell L, Wagner J, eds. Economic models of colorectal cancer screening in average-risk adults. Workshop summary. Washington DC: The National Academies Press; 2005.
24. Drummond MF, Barbieri M, Wong JB. Analytic choices in economic models of treatments for rheumatoid arthritis: what makes a difference? Med Decis Making 2005;25:520-33. (Pubitemid 41384066)
25. Petersen S, Peto V, Scarborough P, Rayner M. Coronary Heart Disease Statistics. London: British Heart Foundation, 2005.
26. Luengo-Fernandez R, Leal J, Gray A, et al. Cost of cardiovascular diseases in the United Kingdom. Heart 2006;92:1384-9. (Pubitemid 44578822)